<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "regulatory t cell" AND "therapy"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: High prevalence of S. pyogenes Cas9-specific T cell sensitization within the adult human population - A balanced effector/regulatory T cell response</h4><p><a href="https://www.biorxiv.org/content/10.1101/295139v1">Link</a></p><p><b>Date:</b> 2018-04-04</p><p><b>Authors:</b> Dimitrios L. Wagner ... Michael Schmueck-Henneresse</p><p><b>Downloads:</b> 1350</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The field of gene therapy has been galvanized by the discovery of the highly efficient and adaptable site-specific nuclease system CRISPR/Cas9 from bacteria.  (1,2) Immunity against therapeutic gene vectors or gene-modifying cargo nullifies the effect of a possible curative treatment and may pose significant safety issues.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Regulatory T cells in solid organ transplantation.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32104579">Link</a></p><p><b>Date:</b> 2020-02-27</p><p><b>Authors:</b> Muhammad Atif ...  Makoto Miyara</p><p><b>Journal:</b> Clin Transl Immunology</p><p><b>IF (7 or above):</b> 8.18</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The induction of graft tolerance remains the holy grail of transplantation.  This is important as chronic allograft dysfunction and the side effects of immunosuppression regimens place a major burden on the lives of transplant patients and their healthcare systems.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunity</h4><p><a href="https://www.biorxiv.org/content/10.1101/862789v2">Link</a></p><p><b>Date:</b> 2019-12-03</p><p><b>Authors:</b> Liliane Khoryati ... Marc A Gavin</p><p><b>Downloads:</b> 351</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Interleukin-2 (IL-2) controls the function of regulatory T cells (Treg) and defects in the IL-2 pathway contribute to multiple autoimmune diseases.  Although IL-2 therapy has been efficacious in certain inflammatory conditions, the capacity for IL-2 to also activate inflammatory effector responses highlights the need for IL-2-based therapeutics with improved Treg-specificity.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Treg-Cell-Derived IL-35-Coated Extracellular Vesicles Promote Infectious Tolerance.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31995748">Link</a></p><p><b>Date:</b> 2020-01-29</p><p><b>Authors:</b> Jeremy A Sullivan ...  William J Burlingham</p><p><b>Journal:</b> Cell Rep</p><p><b>IF (7 or above):</b> 7.7</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Interleukin-35 (IL-35) is an immunosuppressive cytokine composed of Epstein-Barr-virus-induced protein 3 (Ebi3) and IL-12α chain (p35) subunits, yet the forms that IL-35 assume and its role in peripheral tolerance remain elusive.  We induce CBA-specific, IL-35-producing T regulatory (Treg) cells in  ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: IL2 enhances ex-vivo expanded regulatory T cell persistence after adoptive transfer</h4><p><a href="https://www.biorxiv.org/content/10.1101/805531v2">Link</a></p><p><b>Date:</b> 2019-10-15</p><p><b>Authors:</b> Scott N Furlan ... Leslie S Kean</p><p><b>Downloads:</b> 234</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> As regulatory T cell (Treg) adoptive therapy continues to develop clinically, there is a need to determine which immunomodulatory agents pair most compatibly with Tregs to enable persistence and stabilize suppressor function.  Prior work has shown that mechanistic target of rapamycin (mTOR) inhibition can increase stability of thymic Tregs.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/334508v1">Link</a></p><p><b>Date:</b> 2018-05-30</p><p><b>Authors:</b> Thi Thu Phuong Tran ... Eric J Kremer</p><p><b>Downloads:</b> 204</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Following repeated encounters with adenoviruses most of us develop robust humoral and cellular immune responses that are thought to act together to combat ongoing and subsequent infections.  Yet in spite of robust immune responses, adenoviruses establish subclinical persistent infections that can last for decades.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Bcl6 Preserves the Suppressive Function of Regulatory T Cells during Tumorigenesis</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.21.914812v2">Link</a></p><p><b>Date:</b> 2020-01-23</p><p><b>Authors:</b> Yiding Li ... Lifan Xu</p><p><b>Downloads:</b> 241</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> During tumorigenesis, tumor infiltrating regulatory T (Treg) cells restrict the function of effector T cells in tumor microenvironment and thereby promoting tumor growth.  The anti-tumor activity of effector T cells can be therapeutically unleashed, and is now being exploited for the treatment of various types of human cancers.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system</h4><p><a href="https://www.biorxiv.org/content/10.1101/191031v6">Link</a></p><p><b>Date:</b> 2017-09-19</p><p><b>Authors:</b> Aude Burlion ... Gilles Marodon</p><p><b>Downloads:</b> 1227</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Mice reconstituted with a human immune system and bearing human tumors represent a promising model for developing novel cancer immunotherapies.  Here, we used mass cytometry and multi-parametric flow cytometry to characterize human leukocytes infiltrating a human breast cancer tumor model in immunocompromised NOD.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: PI3Kδ inhibition supports memory T cells with enhanced antitumor fitness</h4><p><a href="https://www.biorxiv.org/content/10.1101/166074v1">Link</a></p><p><b>Date:</b> 2017-07-20</p><p><b>Authors:</b> Jacob S. Bowers ... Chrystal M Paulos</p><p><b>Downloads:</b> 579</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibition by Idelalisib (CAL-101) in hematological malignancies directly induces apoptosis in cancer cells and disrupts immunological tolerance by depleting regulatory T cells (Tregs).  Yet, little is known about the direct impact of PI3Kδ blockade on effector T cells from CAL-101 therapy.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile</h4><p><a href="https://www.biorxiv.org/content/10.1101/426221v2">Link</a></p><p><b>Date:</b> 2018-09-30</p><p><b>Authors:</b> Rosa de Groot ... Monika C. Wolkers</p><p><b>Downloads:</b> 559</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Non-small cell lung cancer (NSCLC) is the second most prevalent type of cancer.  With the current treatment regimens, the mortality rate remains high.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: A second generation IL-2 receptor-targeted diphtheria fusion toxin exhibits anti-tumor activity and synergy with anti-PD-1 in melanoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/420158v1">Link</a></p><p><b>Date:</b> 2018-09-17</p><p><b>Authors:</b> Laurene S. Cheung ... William Bishai</p><p><b>Downloads:</b> 474</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Denileukin diftitox (DAB1-389-IL-2, Ontak) is a diphtheria toxin-based fusion protein that depletes CD25-positive cells including regulatory T cells (Tregs) and was approved for the treatment of persistent or recurrent cutaneous T cell lymphoma.  However, the clinical use of denileukin diftitox was limited by vascular leak toxicity and production issues related to drug aggregation and purity.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: An immunoevasive strategy through clinically-relevant pan cancer genomic and transcriptomic alterations of JAK-STAT signaling components</h4><p><a href="https://www.biorxiv.org/content/10.1101/576645v1">Link</a></p><p><b>Date:</b> 2019-03-14</p><p><b>Authors:</b> Wai Hoong Chang ... Alvina G. Lai</p><p><b>Downloads:</b> 338</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Since its discovery almost three decades ago, the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has paved the road for understanding inflammatory and immunity processes related to a wide range of human pathologies including cancer.  Several studies have demonstrated the importance of JAK-STAT pathway components in regulating tumor initiation and metastatic progression, yet, the extent of how genetic alterations influence patient outcome is far from being understood.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Aberrations in Notch-Hedgehog signalling reveal cancer stem cells harbouring conserved oncogenic properties associated with hypoxia and immunoevasion</h4><p><a href="https://www.biorxiv.org/content/10.1101/526202v1">Link</a></p><p><b>Date:</b> 2019-01-21</p><p><b>Authors:</b> Wai Hoong Chang ... Alvina G. Lai</p><p><b>Downloads:</b> 227</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Cancer stem cells (CSCs) have innate abilities to resist even the harshest of therapies.  To eradicate CSCs, parallels can be drawn from signalling modules that orchestrate pluripotency.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity</h4><p><a href="https://www.biorxiv.org/content/10.1101/768796v2">Link</a></p><p><b>Date:</b> 2019-09-15</p><p><b>Authors:</b> Sandra Grund-Gröschke ... Fritz Aberger</p><p><b>Downloads:</b> 183</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Genetic activation of Hedgehog (HH)/GLI signaling causes basal cell carcinoma (BCC), a very frequent non-melanoma skin cancer.  Small molecule targeting of the essential HH effector Smoothened (SMO) proved an efficient medical therapy of BCC, although lack of durable responses and frequent development of drug resistance pose major challenges to anti-HH treatments.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/710434v1">Link</a></p><p><b>Date:</b> 2019-07-22</p><p><b>Authors:</b> Qing Wang ... David J. Klinke</p><p><b>Downloads:</b> 102</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Combining anti-cancer therapies with orthogonal modes of action, such as direct cytotoxicity and immunostimulatory, hold promise for expanding clinical benefit to patients with metastatic disease.  For instance, a chemotherapy agent Oxaliplatin (OXP) in combination with Interleukin-12 (IL-12) can eliminate pre-existing liver metastatic colorectal cancer and protect from relapse in a murine model.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion</h4><p><a href="https://www.biorxiv.org/content/10.1101/610550v1">Link</a></p><p><b>Date:</b> 2019-04-18</p><p><b>Authors:</b> Ansuman T. Satpathy ... Howard Y. Chang</p><p><b>Downloads:</b> 10191</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Understanding complex tissues requires single-cell deconstruction of gene regulation with precision and scale.  Here we present a massively parallel droplet-based platform for mapping transposase-accessible chromatin in tens of thousands of single cells per sample (scATAC-seq).</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Genome-Wide Association Analysis Identifies Genetic Correlates of Immune Infiltrates in Solid Tumors.</h4><p><a href="https://www.biorxiv.org/content/10.1101/106039v2">Link</a></p><p><b>Date:</b> 2017-02-04</p><p><b>Authors:</b> Nathan O. Siemers ... Joseph D Szustakowski</p><p><b>Downloads:</b> 887</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Therapeutic options for the treatment of an increasing variety of cancers have been expanded by the introduction of a new class of drugs, commonly referred to as checkpoint blocking agents, that target the host immune system to positively modulate anti-tumor immune response.  Although efficacy of these agents has been linked to a pre-existing level of tumor immune infiltrate, it remains unclear why some patients exhibit deep and durable responses to these agents therapy while others do not benefit.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/209288v1">Link</a></p><p><b>Date:</b> 2017-10-26</p><p><b>Authors:</b> Zhixian Liu ... Xiaosheng Wang</p><p><b>Downloads:</b> 758</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Triple-negative breast cancer (TNBC) is a high-risk malignancy due to its high capacity for invasion and lack of targeted therapy.  Immunotherapy continues to demonstrate efficacy in a variety of cancers, and thus may be a promising strategy for TNBC given the limited therapeutic options currently available for TNBC.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Cancer stemness, intratumoral heterogeneity, and immune response across cancers</h4><p><a href="https://www.biorxiv.org/content/10.1101/352559v1">Link</a></p><p><b>Date:</b> 2018-06-20</p><p><b>Authors:</b> Alex Miranda ... Brad H Nelson</p><p><b>Downloads:</b> 748</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Regulatory programs that control the function of stem cells are active in cancer and confer properties that promote progression and therapy resistance.  However, the impact of a stem cell-like tumor phenotype ("stemness") on the immunological properties of cancer has not been systematically explored.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Allele-specific silencing ameliorates restrictive cardiomyopathy due to a human myosin regulatory light chain mutation</h4><p><a href="https://www.biorxiv.org/content/10.1101/559468v1">Link</a></p><p><b>Date:</b> 2019-02-24</p><p><b>Authors:</b> Kathia Zaleta-Rivera ... Euan A. Ashley</p><p><b>Downloads:</b> 244</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Restrictive cardiomyopathy (RCM) is a rare heart disease associated with mutations in sarcomeric genes and with phenotypic overlap with hypertrophic cardiomyopathy.  There is no approved therapy.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Integrated analyses of early responses to radiation in glioblastoma identify new alterations in RNA processing and candidate target genes to improve treatment outcomes</h4><p><a href="https://www.biorxiv.org/content/10.1101/863852v2">Link</a></p><p><b>Date:</b> 2019-12-04</p><p><b>Authors:</b> Saket Choudhary ... Luiz O Penalva</p><p><b>Downloads:</b> 187</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: High-dose radiation is the main component of glioblastoma therapy.  Unfortunately, radio-resistance is a common problem and a major contributor to tumor relapse.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Synergistic interplay between PHF8 and HER2 signaling contributes to breast cancer development and drug resistance</h4><p><a href="https://www.biorxiv.org/content/10.1101/682476v1">Link</a></p><p><b>Date:</b> 2019-06-25</p><p><b>Authors:</b> Qi Liu ... Hank Heng Qi</p><p><b>Downloads:</b> 127</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> HER2 plays a critical role in tumorigenesis and is associated with poor prognosis of HER2-positive breast cancers.  Although, anti-HER2 drugs show benefits in breast cancer therapy, de novo or acquired resistance often develop.</p></div></td></div><td></td></tr></table></div><hr></div></body></html>